| How many drug targets are there? JP Overington, B Al-Lazikani, AL Hopkins Nature reviews Drug discovery 5 (12), 993-996, 2006 | 4626 | 2006 |
| Network pharmacology: the next paradigm in drug discovery AL Hopkins Nature chemical biology 4 (11), 682-690, 2008 | 4230 | 2008 |
| The druggable genome AL Hopkins, CR Groom Nature reviews Drug discovery 1 (9), 727-730, 2002 | 4225 | 2002 |
| Ligand efficiency: a useful metric for lead selection AL Hopkins, CR Groom, A Alex Drug discovery today 9 (10), 430-431, 2004 | 2105 | 2004 |
| Quantifying the chemical beauty of drugs GR Bickerton, GV Paolini, J Besnard, S Muresan, AL Hopkins Nature chemistry 4 (2), 90-98, 2012 | 1990 | 2012 |
| Network pharmacology AL Hopkins Nature biotechnology 25 (10), 1110-1111, 2007 | 1390 | 2007 |
| Navigating chemical space for biology and medicine C Lipinski, A Hopkins Nature 432 (7019), 855-861, 2004 | 1264 | 2004 |
| The role of ligand efficiency metrics in drug discovery AL Hopkins, GM Keserü, PD Leeson, DC Rees, CH Reynolds Nature reviews Drug discovery 13 (2), 105-121, 2014 | 1158 | 2014 |
| Global mapping of pharmacological space GV Paolini, RHB Shapland, WP van Hoorn, JS Mason, AL Hopkins Nature biotechnology 24 (7), 805-815, 2006 | 942 | 2006 |
| Automated design of ligands to polypharmacological profiles J Besnard, GF Ruda, V Setola, K Abecassis, RM Rodriguiz, XP Huang, ... Nature 492 (7428), 215-220, 2012 | 876 | 2012 |
| Can we rationally design promiscuous drugs? AL Hopkins, JS Mason, JP Overington Current opinion in structural biology 16 (1), 127-136, 2006 | 596 | 2006 |
| Complexes of HIV-1 reverse transcriptase with inhibitors of the HEPT series reveal conformational changes relevant to the design of potent non-nucleoside inhibitors AL Hopkins, J Ren, RM Esnouf, BE Willcox, EY Jones, C Ross, ... Journal of Medicinal Chemistry 39 (8), 1589-1600, 1996 | 440 | 1996 |
| Genomic-scale prioritization of drug targets: the TDR Targets database F Agüero, B Al-Lazikani, M Aslett, M Berriman, FS Buckner, RK Campbell, ... Nature reviews Drug discovery 7 (11), 900-907, 2008 | 365 | 2008 |
| Unique features in the structure of the complex between HIV-1 reverse transcriptase and the bis (heteroaryl) piperazine (BHAP) U-90152 explain resistance mutations for this … RM Esnouf, J Ren, AL Hopkins, CK Ross, EY Jones, DK Stammers, ... Proceedings of the National Academy of Sciences 94 (8), 3984-3989, 1997 | 282 | 1997 |
| The structure of HIV-1 reverse transcriptase complexed with 9-chloro-TIBO: lessons for inhibitor design J Ren, R Esnouf, A Hopkins, C Ross, Y Jones, D Stammers, D Stuart Structure 3 (9), 915-926, 1995 | 272 | 1995 |
| Predicting promiscuity AL Hopkins Nature 462 (7270), 167-168, 2009 | 201 | 2009 |
| Fragment screening by surface plasmon resonance I Navratilova, AL Hopkins ACS Medicinal Chemistry Letters 1 (1), 44-48, 2010 | 180 | 2010 |
| Design of MKC-442 (emivirine) analogues with improved activity against drug-resistant HIV mutants AL Hopkins, J Ren, H Tanaka, M Baba, M Okamato, DI Stuart, ... Journal of medicinal chemistry 42 (22), 4500-4505, 1999 | 168 | 1999 |
| Validity of ligand efficiency metrics CW Murray, DA Erlanson, AL Hopkins, GM Keserü, PD Leeson, ... ACS medicinal chemistry letters 5 (6), 616-618, 2014 | 142 | 2014 |
| A crowdsourcing evaluation of the NIH chemical probes TI Oprea, CG Bologa, S Boyer, RF Curpan, RC Glen, AL Hopkins, ... Nature chemical biology 5 (7), 441-447, 2009 | 140 | 2009 |
Colin R. Groom.Подтвержден адрес электронной почты в домене wsh.nhs.uk
